Table 1.
Overall and group demographic and clinical data at study entry
| Overall | NE | LE | GR | HE | PR | |
|---|---|---|---|---|---|---|
|
Age, years * |
60 ± 14 |
53 ± 14 |
57 ± 14 |
60 ± 15 |
64 ±12 |
69 ± 11 |
|
Females, n (%) |
109 (36.1) |
6 (17.1) |
16 (33.3) |
61 (38.1) |
17 (41.5) |
9 (50) |
|
Diabetes, n (%) |
56 (18.5) |
7 (20.0) |
15 (31.0) |
23 (14.3) |
8 (16.3) |
3 (16.7) |
|
CAD, n (%) |
108 (35.8) |
9 (25.7) |
17 (35.4) |
56 (35) |
18 (43.9) |
8 (44.4) |
|
HT, n (%) * |
267 (88.4) |
26 (74.3) |
44 (91.7) |
146 (91.3) |
34 (82.9) |
17 (94.4) |
|
PVD, n (%) |
70 (23.3) |
4 (11.4) |
16 (33.3) |
33 (20.6) |
11 (26.8) |
6 (33.3) |
|
CVA, n (%) * |
38 (12.7) |
2 (5.7) |
6 (12.5) |
17 (10.6) |
12 (29.3) |
1 (5.6) |
|
COPD, n (%) |
29 (9.6) |
4 (11.4) |
3 (6.3) |
13 (8.1) |
7 (17.1) |
2 (11.1) |
|
Dyslipidemia, n (%) |
118 (39.1) |
8 (22.9) |
24 (50) |
60 (37.5) |
17 (41.5) |
9 (50) |
|
BMI kg/m2 * |
25.9 ± 5.6 |
27.1 ± 7.7 |
27.5 ± 5.9 |
25.1 ± 4.7 |
24.6 ± 4.4 |
28.9 ± 6.9 |
|
Obesity, n (%) * |
18 (6) |
3 (8.6) |
6 (12.5) |
6 (3.8) |
0 |
3 (16.7) |
|
Previous transplant, n(%)* |
10 (28.6) |
4 (8.3) |
19 (11.9) |
5 (12.2) |
1 (5.6) |
39 (12.9) |
|
HD, n (%) * |
244 (80.8) |
24 (68.6) |
30 (62.5) |
135 (84.4) |
38 (92.7) |
17 (94.4) |
|
Duration of ESKD (months) |
34 (18–60) |
49 (28–111) |
26 (15–56) |
34 (17–60) |
31 (19–54) |
31 (23–58) |
| Time on dialysis (months) | 33 (18–58) | 41 (27–88) | 36 (18–66) | 37 (22–59) | 31 (23–58) | 35 (18–61) |
BMI: body mass index, CAD: coronary artery disease, HT: hypertension, PVD: peripheral vascular disease, CVA: past cerebrovascular accident, COPD: chronic obstructive pulmonary disease, Obesity: BMI > 30 kg/m2, HD: haemodialysis, ESKD: end stage kidney disease *: p < 0.05 for between-group analysis. Data are displayed as mean ± SD, n (%), or median (25th-75th quartile), as indicated.